Date: 06.09.2025

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 30 of the Listing Regulations, this is to inform that, pursuant to the resolution passed by the shareholders of the Company through postal ballot on March 24, 2025, the Company has registered the sale deed for the immovable property/ies, for sale of below mentioned immovable property/ies, in particular the pieces and parcels of land ("the land parcels");

- Land admeasuring 4040.00 sq. mtrs situated at Plot No 47-P2 of Hirehalli Industrial Area, situated in Sy. No. Parts 52 and 53 of Manchkalkuppe Village, Uradegere Hobli, Tumkur Taluk and District.
- Land admeasuring 5901 Sq.Mtrs situated at Plot No.47 of Sy.No.53, situated at Manchakalkuppe Village, Urdagere Hobli, Tumkur Taluk, Tumkur District.
- Land admeasuring 4034.00 Sq. mts. (approx.) situated at plot No. 46 of Hirehalli Industrial Area, situated in Sy. No. parts of 52 and 53 of Manchakalkuppe Village, Urdagere Hobli, Tumkur Taluk, Tumkur District.

The proposal to sell the said land was approved by the Board of Directors earlier at its meeting held on February 12, 2025, as duly mentioned in our intimation about outcome of the said meeting of the Board by passing an enabling resolution to sell the land parcels.

As no business operations of the Company are carried out on the said land parcels being sold, the said sale will not have any impact on the business operations of the Company. Further the sale of the said land parcels constitute as an undertaking in terms of section 180(1)(a) of the Companies Act, 2013 and Regulation 37A of Listing Regulations.

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular dated November 11, 2024, are provided as Annexure A.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat (Company Secretary & Compliance Officer)

Annexure A

## Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024;

S. N	Particulars	Details
a	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Sale of land properties and hence, the disclosure under this clause is not applicable.
b	Date on which the agreement for sale has been entered into	The company has entered into sale deed with the buyer on August 29, 2025.
С	The expected date of completion of sale/disposal	Sale completed on September 06, 2025.
d	Consideration received from such sale/disposal	Rs. 19.56 Crores (Rupees Nineteen Crores Fifty Six Lakhs Only)
e	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Dr. S. N. Vinaya Babu, Chairman and Non-Executive & Non Independent Director of the Company ("the Buyer"), Related party of the Company.
		Currently the buyer does not belong to the promoter/promoter group/group companies.
		The Buyer had given the open offer to the public shareholders of the company, Pursuant to the completion of open offer, the buyer will be classified as the Promoters/Promoter Group of our Company.
f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes. Dr. S. N. Vinaya Babu is a related party of the Company and the transaction falls within ambit of related party transaction.
		The consideration for the transaction has been at arm's length.
g	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement	Yes. The sale of land and building is not part of a Scheme of Arrangement.
		Further, the sale of the said land parcels attract the terms of regulation 37A of the Listing Regulations, as it constitute an undertaking for the Company under section 180 (1)(a) of the Companies Act, 2013.
		The approval of the shareholders was obtained by the Company by means of passing resolution through postal ballot means on March 24, 2025.



h	Additionally, in case of a slump sale,	Not Applicable
	indicative disclosures provided for	
	amalgamation/merger, shall be disclosed	
	by the listed entity with respect to such	
	slump sale.	

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat (Company Secretary & Compliance Officer)